CClinicalTrials.gg
CompletedNCT06954051Updated Aug 28, 2025

ERFs Game-based Assessment in AYAs: Validation of Game-based Assessment of Emotion Regulation Abilities

An interventional study of REThink Life in Emotion Regulation, sponsored by Babes-Bolyai University. Completed at 1 site in Romania. Open to participants aged 10 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Babes-Bolyai University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Not applicable
Ages
10 Years to 24 Years
Sex
All
01

Study summary

This activity will have the objective of establishing the validity of in-game emotion regulation abilities assessment for adolescents and young adults.

Read the detailed description

Each level of the REThink LIFE online game dedicated to training a specific ER skill has an assessment task for emotion recognition, stress reactivity, mindfulness and positive attention abilities. The aim of this study will be to investigate the validity of in-game performance measurements or scores as indicators of adolescents and young adults' emotion regulation abilities.

02

Conditions studied

  • Emotion Regulation

Browse trials for

03

In context

Emotional Regulation

225 studies on the registry are indexed under Emotional Regulation; 121 are open to participants now.

This study's enrollment of 230 is above the median of 74 across 211 interventional studies indexed under Emotional Regulation.

Browse Emotional Regulation studies →

Lead sponsor

Babes-Bolyai University is the lead sponsor of 48 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • adolescents and young adults with between 10 and 24 years old provided with written parental consent where applicable

Exclusion criteria

Exclusion Criteria:

  • intellectual disability or physical limitations precluded the use of the computer program
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (actual)

Study arms

  • Other
    REThink Life

    The participants will complete the scale measurements after receiving the four levels of the REThink Life game, each focusing on an emotion regulation skill and an associated assessment system.

    Other: REThink Life

Interventions

  • OtherREThink Life

    REThink Life is a therapeutic game developed by David and collaborators (2019) and it is composed of four levels, each training a different emotion regulation ability (emotion recognition, mindfulness, distinguishing between rational and irrational thoughts, and positive attention bias).

06

What researchers measure

Primary outcomes

  1. Emotion regulation

    The Cognitive Emotion Regulation Questionnaire (CERQ-short) is an 18-item scale assessing nine different emotion regulation strategies, namely Self-blame, Other-blame, Rumination, Catastrophizing, Positive refocusing, Planning, Positive reappraisal, Putting into perspective and Acceptance. Children and adolescents were asked to express the frequency of using each strategy on a 5-point Likert-type scale, from 1 ("almost never") to 5 ("almost always"). Higher scores on adaptive strategies (e.g., positive reappraisal, refocus on planning, positive refocusing, putting into perspective, acceptance) are equivalent to a better outcome (more adaptive coping). Higher scores on maladaptive strategies (e.g., rumination, catastrophizing, self-blame, other-blame) are equivalent to worse outcomes (less adaptive coping).

    Time frame: Baseline

  2. Behavioral difficulties

    The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for children aged 2 to 17 years old, encompassing emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior. Total difficulties score: Sum of all subscales except Prosocial → Range: 0 to 40. Prosocial score is reported separately → Range: 0 to 10. Higher scores on total difficulties and the four problem subscales are equivalent to worse outcomes. Higher scores on the prosocial subscale are equivalent to better outcomes.

    Time frame: Baseline

  3. Stress

    The Adolescent Stress Scale (ADOSS) will be used to capture students' level of stress in the following domains: personal, academic, family, and social. Total score ranges from 20 to 100, with higher scores indicating higher levels of stress.

    Time frame: Baseline

07

Study locations

1 site
  • Babes-Bolyai University
    Cluj-Napoca, Cluj 400015, Romania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06954051
Lead sponsor
Babes-Bolyai University
Collaborators
The Executive Agency for Higher Education, Research, Development and Innovation Funding
Responsible party
Oana David (Professor PhD, Babes-Bolyai University) — Principal investigator
First posted
May 1, 2025
Start date
Feb 15, 2025
Primary completion
Jun 15, 2025
Completion
Jun 30, 2025
Last update
Aug 28, 2025

Study contacts

Oana A. David, Ph.D
principal investigator · Babes-Bolyai University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion